Celgene, Epizyme extend HMT collaboration

Celgene Corp. (NASDAQ:CELG) and partner Epizyme Inc. (NASDAQ:EPZM) extended their existing research collaboration by three years, giving Celgene options to license Epizyme's histone methyltransferase inhibitors against three undisclosed targets. At the time of an IND submission for each target, Celgene can license global rights for two targets and ex-U.S. rights for the third.

Epizyme will receive a $10 million extension fee and is eligible for $610 million in milestones, plus royalties. ...